HNRNPA1 and neurodegenerative disease: This could potentially guide therapeutic solutions for neurodegenerative diseases, which typically involve the liquid–solid transition of relevant biomolecular condensates formed by various proteins and nucleic acids, such as hnRNPA1, TDP-43 and FUS19,57–59.